Table 3

Endpoints at 4 and 26 weeks

Control group
(1x IVIg) n=199
Early second IVIg group
(2x IVIg) n=20
Late second IVIg group
(2x IVIg) n=18
P value
Secondary endpoints
 Improving ≥1 score on GBS disability sore, n (%) at:
 4 weeks51/167 (31)3/18 (17)0 (0)0.002*†
 26 weeks127/145 (88)12/16 (75)4/11 (36)0.001*†
 Able to walk independently, n (%) at:
 26 weeks99/154 (64)11/16 (69)2/11 (18)0.01*†‡
 Change in MRC sum score (median, IQR) at:
 4 weeks4 (−8 to 12)−2 (−23 to 10)−4 (−36 to 2)<0.001
 26 weeks18 (12–32)27 (3–48)11 (−4 to 21)0.06
 Requiring ventilation, n (%)88 (44)16 (80)12 (67)0.003§
 GBS related mortality at 6 months, n (%)9/154 (6)0 (0)0 (0)0.44
 TRF¶, n (%)4 (2)2 (10)1 (6)0.11
 Complications after first IVIg course, n (%)
 Headache3 (2)0 (0)1 (6)
 Shivering1 (1)0 (0)0 (0)
 Nausea/vomiting1 (1)0 (0)0 (0)
 Hallucinations/psychosis0 (0)1 (5)0 (0)
 Hypo/hypertension1 (1)0 (0)0 (0)
 Complications after second IVIg course, n (%)
 Headache0 (0)0 (0)1 (6)
  • *P value derived from unadjusted binary logistic regression analysis.

  • †P value < 0.05 for control group versus late second IVIg group.

  • ‡P value < 0.05 for early versus late second IVIg group.

  • §P value < 0.05 for control group versus early second IVIg group.

  • ¶The second IVIg course in the early and late groups was not given because of the TRF.

  • GBS, Guillain-Barré syndrome; IVIg, intravenous immunoglobulin; MRC, medical research council; TRF, treatment related fluctuation.